Hydrogels comprising cell adhesive peptides and methods of use thereof
US-2024376438-A1 · Nov 14, 2024 · US
Clerodendrum viscosum and methods of use
US10059924B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10059924-B2 |
| Application number | US-201314079250-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 13, 2013 |
| Priority date | Nov 13, 2012 |
| Publication date | Aug 28, 2018 |
| Grant date | Aug 28, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides for a composition and formulations comprising an extract from Clerodendrum viscosum , and a method of obtaining the extract. The present invention also provides for a method of treating any disease where uncontrolled cellular proliferation occurs, such as cancers. In particular, the present invention provides a method for treating cervical cancer. The present invention also provides methods to inhibit proliferation and induce apoptosis of cancer cells.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of inhibiting cervical cancer cell proliferation, said method comprising contacting said cell with an effective amount of a composition comprising an aqueous protein extract of Clerodendrum viscosum root; wherein the extract comprises a glycoprotein having a molecular weight of about 25 kDa as determined by MALDI-TOF; and induces caspase-3 activation. 2. The method according to claim 1 , wherein the glycoprotein comprises a terminal α-D-mannosyl group. 3. The method according to claim 1 , wherein the glycoprotein comprises a terminal α-D-glucosyl group. 4. The method according to claim 1 , wherein the extract induces apoptosis of cancer cells. 5. The method according to claim 1 , wherein the method further comprises administering a chemotherapeutic agent to the cervical cancer cells. 6. The method according to claim 1 , wherein the composition comprises at least one pharmaceutically acceptable carrier. 7. The method according to claim 1 , wherein the MALDI-TOF data comprises m/z peaks at about 6.9 kDa, about 9.2 kDa, about 13.5 kDa, and about 25 kDa.
Assignees
Inventors
Classifications
- C12N5/0693Primary
Tumour cells; Cancer cells · CPC title
from plants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10059924B2 cover?
- The present invention provides for a composition and formulations comprising an extract from Clerodendrum viscosum , and a method of obtaining the extract. The present invention also provides for a method of treating any disease where uncontrolled cellular proliferation occurs, such as cancers. In particular, the present invention provides a method for treating cervical cancer. The present inv…
- Who is the assignee on this patent?
- The City Univ Of New York, Univ City New York Res Found
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0693. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).